Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Deutsche Bank Keeps Their Buy Rating on Novartis AG (NOVN)

Tipranks - Tipranks - Tue Mar 31, 4:32AM CDT

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF135.00.

End of Quarter Sale - 50% Off TipRanks

Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG. According to TipRanks, Papadakis has an average return of 3.5% and a 51.16% success rate on recommended stocks.

In addition to Deutsche Bank , Novartis AG also received a Buy from Bank of America Securities’s Sachin Jain in a report issued on March 26. However, on March 27, Barclays maintained a Hold rating on Novartis AG (Six Swiss: NOVN).

See today’s best-performing stocks on TipRanks >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).